MX347972B - Anticuerpos estables y solubles que inhiben el vegf. - Google Patents

Anticuerpos estables y solubles que inhiben el vegf.

Info

Publication number
MX347972B
MX347972B MX2013004871A MX2013004871A MX347972B MX 347972 B MX347972 B MX 347972B MX 2013004871 A MX2013004871 A MX 2013004871A MX 2013004871 A MX2013004871 A MX 2013004871A MX 347972 B MX347972 B MX 347972B
Authority
MX
Mexico
Prior art keywords
stable
antibodies
vegf
inhibiting vegf
soluble antibodies
Prior art date
Application number
MX2013004871A
Other languages
English (en)
Inventor
Urech David
Borras Leonardo
Gunde Tea
Original Assignee
Esbatech Alcon Biomed Res Unit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech Alcon Biomed Res Unit filed Critical Esbatech Alcon Biomed Res Unit
Publication of MX347972B publication Critical patent/MX347972B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

La presente invención se refiere a inmunoaglutinantes anti-VEGF solubles y estables que comprenden CDRs de anticuerpos monoclonales de conejo. Dichos anticuerpos se diseñan para el diagnóstico y/o tratamiento de desórdenes mediados por el VEGF. También se dan a conocer hibridomas, ácidos nucleicos, vectores y células hospederas para la expresión de los anticuerpos recombinantes de la invención, métodos para aislar los mismos y el uso de dichos anticuerpos en la medicina.
MX2013004871A 2008-06-25 2009-06-25 Anticuerpos estables y solubles que inhiben el vegf. MX347972B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7569708P 2008-06-25 2008-06-25
US7569208P 2008-06-25 2008-06-25
US13321208P 2008-06-25 2008-06-25
US15504109P 2009-02-24 2009-02-24
PCT/CH2009/000220 WO2009155724A2 (en) 2008-06-25 2009-06-25 Stable and soluble antibodies inhibiting vegf

Publications (1)

Publication Number Publication Date
MX347972B true MX347972B (es) 2017-05-22

Family

ID=41209803

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013004871A MX347972B (es) 2008-06-25 2009-06-25 Anticuerpos estables y solubles que inhiben el vegf.
MX2011000011A MX2011000011A (es) 2008-06-25 2009-06-25 Anticuerpos estables y solubles que inhiben el vegf.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2011000011A MX2011000011A (es) 2008-06-25 2009-06-25 Anticuerpos estables y solubles que inhiben el vegf.

Country Status (26)

Country Link
US (5) US8349322B2 (es)
EP (3) EP3216803B1 (es)
JP (7) JP5956752B2 (es)
KR (8) KR101737466B1 (es)
CN (3) CN110372792A (es)
AU (1) AU2009264565C1 (es)
BR (1) BRPI0914251B1 (es)
CA (2) CA2727839C (es)
CL (1) CL2010001544A1 (es)
CY (3) CY1118829T1 (es)
DK (2) DK3216803T3 (es)
ES (2) ES2793008T3 (es)
HK (1) HK1150844A1 (es)
HR (2) HRP20170615T1 (es)
HU (3) HUE050230T2 (es)
LT (3) LT3216803T (es)
MX (2) MX347972B (es)
NL (1) NL301058I2 (es)
NO (1) NO2020021I1 (es)
PH (1) PH12015501593A1 (es)
PL (2) PL2307454T3 (es)
PT (2) PT3216803T (es)
RU (6) RU2588467C3 (es)
SI (2) SI2307454T1 (es)
WO (1) WO2009155724A2 (es)
ZA (1) ZA201008594B (es)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101482483B1 (ko) 2006-04-07 2015-01-15 에르피오 세러퓨틱스 인코포레이티드 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도
EP3216803B1 (en) 2008-06-25 2020-03-11 Novartis Ag Stable and soluble antibodies inhibiting vegf
CN102164958A (zh) 2008-06-25 2011-08-24 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 使用通用抗体构架进行的兔抗体的人源化
JP6100463B2 (ja) 2008-06-25 2017-03-22 エスバテック − ア ノバルティス カンパニー エルエルシー ＴＮＦαを阻害する安定かつ可溶性の抗体
US8637022B2 (en) 2008-06-30 2014-01-28 Esbatech, An Alcon Biomedical Research Unit Llc Functionalized polypeptides
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
KR101595808B1 (ko) 2009-02-24 2016-02-19 에스바테크 - 어 노바티스 컴파니 엘엘씨 세포-표면 항원의 면역결합제를 동정하는 방법
EA020621B1 (ru) 2009-06-22 2014-12-30 Амген Инк. Рефолдинг белков с использованием химически контролируемого окислительно-восстановительного состояния
EP3660032A1 (en) 2009-06-25 2020-06-03 Amgen, Inc Capture purification processes for proteins expressed in a non-mammalian system
WO2012054077A2 (en) * 2010-10-19 2012-04-26 Mayo Foundation For Medical Education And Research Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2013038156A1 (en) * 2011-09-16 2013-03-21 Ucb Pharma S.A. Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
EP2766043A4 (en) 2011-10-13 2015-06-10 Aerpio Therapeutics Inc METHOD FOR THE TREATMENT OF CAPILLARY LECKSYNDROME AND CANCER
EP2809344B1 (en) 2012-02-02 2016-08-24 ESBATech - a Novartis Company LLC Antibody-containing sustained-release formulation for ocular administration
ES2896493T3 (es) 2012-07-13 2022-02-24 Roche Glycart Ag Anticuerpos biespecíficos anti-VEGF/anti-ANG-2 y su uso en el tratamiento de enfermedades vasculares oculares
EP2935589A1 (en) 2012-12-18 2015-10-28 Novartis AG Compositions and methods that utilize a peptide tag that binds to hyaluronan
EP3693381A1 (en) 2013-02-18 2020-08-12 Vegenics Pty Limited Ligand binding molecules and uses thereof
KR101541478B1 (ko) * 2013-05-31 2015-08-05 동아쏘시오홀딩스 주식회사 항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
IL293477B1 (en) * 2013-06-26 2024-07-01 Numab Therapeutics AG New frameworks for antibodies
EP3628373A1 (en) 2013-07-12 2020-04-01 IVERIC bio, Inc. Methods for treating or preventing opthalmological conditions
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
EP3143044A1 (en) 2014-05-12 2017-03-22 Formycon AG Pre-filled plastic syringe containing a vegf antagonist
EP3160991A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
WO2015198243A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
KR102390359B1 (ko) 2014-09-29 2022-04-22 삼성전자주식회사 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
TWI806150B (zh) * 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
EA201791029A1 (ru) 2014-11-10 2017-12-29 Дженентек, Инк. Антитела против интерлейкина-33 и их применение
US10894083B2 (en) * 2015-01-28 2021-01-19 Pfizer Inc. Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation
EP3283517A4 (en) 2015-04-16 2019-03-06 Alder Biopharmaceuticals, Inc. ANTI-PACAP ANTIBODIES AND USES THEREOF
US10851399B2 (en) * 2015-06-25 2020-12-01 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
ES2913530T3 (es) 2015-08-12 2022-06-02 Novartis Ag Métodos para tratar trastornos oftálmicos
CA3001362C (en) 2015-10-30 2020-10-13 Genentech, Inc. Anti-htra1 antibodies and methods of use thereof
EP3375875A4 (en) * 2015-11-09 2018-12-05 National University Corporation Kyoto Institute of Technology SEPARATING AGENT FOR HUMAN SERUM-DERIVED IgG POLYCLONAL ANTIBODIES, AND METHOD FOR SEPARATING HUMAN SERUM-DERIVED IgG POLYCLONAL ANTIBODIES USING SAME
MX2018006092A (es) 2015-11-18 2019-01-31 Formycon Ag Envase farmacéutico precargado que comprende una formulación líquida de un antagonista del vegf.
BR112018010005A2 (pt) 2015-11-18 2018-11-21 Formycon Ag seringa pré-carregada, e, kit
WO2018218013A2 (en) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
US11654046B2 (en) 2015-11-18 2023-05-23 Sio2 Medical Products, Inc. Pharmaceutical package for ophthalmic formulations
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
WO2017119434A1 (ja) 2016-01-06 2017-07-13 株式会社オーダーメードメディカルリサーチ Ｖｅｇｆとｎｒｐ１との結合を阻害する抗体
KR102293755B1 (ko) 2016-01-06 2021-08-24 오더-메이드 메디컬 리서치 인코포레이티드 고친화성 항vegf 항체
USD789171S1 (en) 2016-01-21 2017-06-13 Nomis Llc Right angle drive
US10576128B2 (en) 2016-01-26 2020-03-03 Formycon Ag Liquid formulation of a VEGF antagonist
BR112018015826A2 (pt) * 2016-02-05 2019-01-02 The Board Of Regents Of The Univ Texas System anticorpos monoclonais específicos egfl6 e métodos de seu uso
WO2017156423A2 (en) * 2016-03-11 2017-09-14 Integrated Biotherapeutics, Inc. Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever
EP3222673A1 (de) * 2016-03-23 2017-09-27 LANXESS Deutschland GmbH Metallazopigmente
AU2017250807A1 (en) 2016-04-15 2018-10-25 H. Lundbeck A/S. Anti-PACAP antibodies and uses thereof
MA45562B1 (fr) 2016-06-30 2024-05-31 Celltrion Inc Préparation pharmaceutique liquide stable
EP3481963A1 (en) 2016-07-08 2019-05-15 Genentech, Inc. Methods for diagnosing and treating cancer by means of the expression status and mutational status of nrf2 and downstream target genes of said gene.
JP7046089B2 (ja) * 2017-03-09 2022-04-01 マブ ディスカバリー ゲゼルシャフト ミット ベシュレンクテル ハフツング ヒトｉｌ－１ｒ７に特異的に結合する抗体
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
MX2019013750A (es) 2017-05-19 2020-07-20 Council Scient Ind Res Un metodo para producir ranibizumab humanizado recombinante replegado.
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
WO2018217995A1 (en) 2017-05-24 2018-11-29 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
SG11201912865VA (en) * 2017-06-25 2020-01-30 Systimmune Inc Multi-specific antibodies and methods of making and using thereof
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
CN111770999A (zh) 2017-11-27 2020-10-13 4D分子治疗有限公司 腺相关病毒变体衣壳和用于抑制血管生成的应用
WO2019129677A1 (en) 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Anti-vegf antibodies and methods of use
US11078283B2 (en) 2018-01-17 2021-08-03 Apexigen, Inc. Anti-PD-L1 antibodies and methods of use
CN111867631A (zh) 2018-03-16 2020-10-30 诺华股份有限公司 治疗眼部疾病的方法
JP2021517583A (ja) * 2018-04-06 2021-07-26 イーライ リリー アンド カンパニー 小児患者における癌の治療のためのラムシルマブ
WO2020047462A2 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Methods of treating aging-related disorders
CN113365663A (zh) 2018-08-30 2021-09-07 Hcw生物科技公司 单链嵌合多肽和其用途
EP3844181A1 (en) 2018-08-30 2021-07-07 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
JP2022500084A (ja) * 2018-09-13 2022-01-04 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 新規のｌｉｌｒｂ４抗体およびその使用
JP2022502367A (ja) 2018-09-24 2022-01-11 エアーピオ ファーマシューティカルズ， インコーポレイテッド ＨＰＴＰ−β（ＶＥ−ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体
BR112021011290A2 (pt) 2018-12-18 2021-11-03 Novartis Ag Formulação de solução de proteína contendo alta concentração de um anticorpo anti-vegf
USD907455S1 (en) 2019-05-21 2021-01-12 Nomis Llc Right angle drive attachment
USD907456S1 (en) 2019-05-21 2021-01-12 Nomis Llc Right angle drill attachment
AU2020294797A1 (en) 2019-06-21 2021-12-23 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
US20240052024A1 (en) 2019-09-13 2024-02-15 Novartis Ag Methods for treating ocular diseases
JP2022553640A (ja) 2019-10-10 2022-12-26 コディアック サイエンシーズ インコーポレイテッド 眼障害を処置する方法
US20210268022A1 (en) 2020-02-11 2021-09-02 HCW Biologics, Inc. Methods of activating regulatory t cells
JP2023519106A (ja) 2020-02-11 2023-05-10 エイチシーダブリュー バイオロジックス インコーポレイテッド クロマトグラフィー樹脂およびその使用
JP2023513573A (ja) 2020-02-11 2023-03-31 エイチシーダブリュー バイオロジックス インコーポレイテッド 加齢性および炎症性疾患を治療する方法
EP4110819A1 (en) * 2020-02-28 2023-01-04 Apexigen, Inc. Anti-sirpa antibodies and methods of use
CA3175140A1 (en) * 2020-03-12 2021-09-16 Immune-Onc Therapeutics, Inc. Novel anti-lilrb4 antibodies and derivative products
JP2023517345A (ja) 2020-03-13 2023-04-25 ジェネンテック， インコーポレイテッド 抗インターロイキン－３３抗体及びその使用
US20230174666A1 (en) 2020-04-29 2023-06-08 HCW Biologics, Inc. Anti-cd26 proteins and uses thereof
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
AU2021283199A1 (en) 2020-06-01 2023-01-05 HCW Biologics, Inc. Methods of treating aging-related disorders
EP4182025A1 (en) 2020-07-16 2023-05-24 Novartis AG Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
WO2022081835A1 (en) 2020-10-15 2022-04-21 Genentech, Inc. Hyaluronic acid binding derivatives of versican (vg1) for long acting delivery of therapeutics
TW202237181A (zh) 2020-11-25 2022-10-01 瑞士商諾華公司 治療眼部疾病之方法
WO2022201084A1 (en) 2021-03-26 2022-09-29 Novartis Ag Methods for treating ocular diseases
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
KR20230094450A (ko) 2021-12-21 2023-06-28 한림대학교 산학협력단 항-cldn18.2를 포함하는 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법
WO2023168363A1 (en) 2022-03-02 2023-09-07 HCW Biologics, Inc. Method of treating pancreatic cancer
TW202337496A (zh) 2022-03-17 2023-10-01 瑞士商諾華公司 治療新生血管性年齡相關性黃斑點退化之方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
OA10149A (en) 1991-03-29 1996-12-18 Genentech Inc Vascular endothelial cell growth factor antagonists
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
DE69233739D1 (de) 1992-10-28 2008-08-07 Genentech Inc Verwendung von Antagonisten des Zellwachstumsfaktors VEGF
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
CA2243459C (en) 1996-02-09 2002-09-17 Basf Aktiengesellschaft Human antibodies that bind human tnf.alpha.
JP2000516452A (ja) * 1996-07-16 2000-12-12 プリュックテュン，アンドレアス 可溶性が増大した免疫グロブリンスーパーファミリードメインおよびフラグメント
US6986890B1 (en) 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
PT1325932E (pt) * 1997-04-07 2005-06-30 Genentech Inc Anticorpos anti-vegf
WO1998045332A2 (en) * 1997-04-07 1998-10-15 Genentech, Inc. Humanized antibodies and methods for forming humanized antibodies
US7365166B2 (en) 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
WO2000034337A1 (en) 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Humanized monoclonal antibodies against vascular endothelial cell growth factor
AU3737500A (en) 1999-03-12 2000-09-28 Genentech Inc. Method of preventing the death of retinal neurons and treating ocular diseases
JP4926320B2 (ja) 1999-04-28 2012-05-09 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｖｅｇｆの選択的阻害による癌処置のための組成物および方法
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
EP1233790A2 (en) 1999-10-22 2002-08-28 Ludwig Institute For Cancer Research A33 antigen specific immunoglobulin products in cancer therapy
ES2225269T3 (es) 1999-12-28 2005-03-16 Esbatech Ag Intracuerpos con esqueleto definido que es estable en un ambiente reductor y aplicaciones de los mismos.
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
DE10201450B4 (de) 2002-01-16 2004-09-02 Infineon Technologies Ag Carry-Skip-Addierer für verschlüsselte Daten
US6576941B1 (en) 2002-02-20 2003-06-10 Samsung Electronics Co., Ltd. Ferroelectric capacitors on protruding portions of conductive plugs having a smaller cross-sectional size than base portions thereof
CN1187373C (zh) * 2002-03-20 2005-02-02 上海中信国健药业有限公司 人源化抗血管内皮生长因子单克隆抗体及其制法和药物组合物
US8420353B2 (en) 2002-03-22 2013-04-16 Aprogen, Inc. Humanized antibody and process for preparing same
CN103739706B (zh) * 2002-05-22 2015-11-18 艾斯巴技术-诺华有限责任公司 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
WO2004016740A2 (en) * 2002-08-15 2004-02-26 Epitomics, Inc. Humanized rabbit antibodies
KR20180014881A (ko) 2003-05-30 2018-02-09 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
US20050048578A1 (en) * 2003-06-26 2005-03-03 Epitomics, Inc. Methods of screening for monoclonal antibodies with desirable activity
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) * 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
WO2005016950A1 (en) * 2003-08-07 2005-02-24 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
DK2476427T3 (en) 2004-08-02 2018-05-07 Zenyth Operations Pty Ltd METHOD OF TREATING CANCER INCLUDING A VEGF-B ANTAGONIST
EP2319492A3 (en) 2004-10-21 2011-08-10 Genentech, Inc. Method for treating intraocular neovascular diseases
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
KR20080068004A (ko) * 2005-08-15 2008-07-22 아라나 테라퓨틱스 리미티드 뉴 월드 영장류 구조형성영역을 가진 조작 항체
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
WO2007140534A1 (en) * 2006-06-08 2007-12-13 Csl Limited Vegf-a cross-reactive anti- vegf-b antibodies as antagonists of vegf-a and vegf-b signalling
ES2820837T3 (es) 2006-07-10 2021-04-22 Esbatech Alcon Biomed Res Unit Anticuerpos scFv que pasan las capas epitelial y/o endotelial
US20100111963A1 (en) 2006-11-10 2010-05-06 Genentech, Inc. Method for treating age-related macular degeneration
US7553486B2 (en) 2006-11-13 2009-06-30 Paul Theodore Finger Anti-VEGF treatment for radiation-induced vasculopathy
JP2010513566A (ja) 2006-12-19 2010-04-30 ジェネンテック， インコーポレイテッド アジュバント療法およびネオアジュバント療法のためのｖｅｇｆ特異的アンタゴニストと初期ステージ腫瘍の治療
CN101668771B (zh) 2007-03-12 2013-08-21 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 单链抗体的基于序列的工程改造和最优化
US8877186B2 (en) 2007-06-06 2014-11-04 Domantis Limited Polypeptides, antibody variable domains and antagonists
KR20100018040A (ko) 2007-06-06 2010-02-16 도만티스 리미티드 프로테아제 내성 폴리펩티드를 선택하는 방법
SI2158315T1 (sl) 2007-06-25 2016-05-31 Esbatech, An Alcon Biomedical Research Unit Llc Postopki za spreminjanje protiteles in spremenjena protitelesa z izboljšanimi funkcionalnimi lastnostmi
KR101530723B1 (ko) 2007-06-25 2015-06-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화
KR101581244B1 (ko) * 2008-03-26 2015-12-31 에피토믹스, 인코포레이티드 항―ｖｅｇｆ 항체
EP3216803B1 (en) * 2008-06-25 2020-03-11 Novartis Ag Stable and soluble antibodies inhibiting vegf
CN102164958A (zh) * 2008-06-25 2011-08-24 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 使用通用抗体构架进行的兔抗体的人源化
PL2307455T3 (pl) 2008-06-25 2017-09-29 Esbatech, An Alcon Biomedical Research Unit Llc Optymalizacja rozpuszczalności cząsteczek immunowiążących
CN102088958A (zh) * 2008-07-10 2011-06-08 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 用于大分子的增强的递送的方法和组合物
BR112012017051A2 (pt) * 2009-12-23 2017-12-05 Esbatech Alcon Biomed Res Unit método para diminuir a imunogenicidade

Also Published As

Publication number Publication date
JP6527128B2 (ja) 2019-06-05
SI3216803T1 (sl) 2020-07-31
CY1123028T1 (el) 2021-10-29
CY2020026I2 (el) 2020-11-25
AU2009264565B2 (en) 2014-05-08
RU2019120079A3 (es) 2020-12-28
CN104961828B (zh) 2019-03-26
US20120014958A1 (en) 2012-01-19
AU2009264565C1 (en) 2022-01-27
RU2696972C1 (ru) 2019-08-07
LTC2307454I2 (lt) 2021-05-25
KR20200108922A (ko) 2020-09-21
US20200172608A1 (en) 2020-06-04
ZA201008594B (en) 2012-02-29
JP2017055774A (ja) 2017-03-23
ES2793008T3 (es) 2020-11-12
US20150274820A1 (en) 2015-10-01
KR20190092630A (ko) 2019-08-07
CY2020026I1 (el) 2020-11-25
HUE050230T2 (hu) 2020-11-30
DK3216803T3 (da) 2020-06-02
NL301058I2 (nl) 2020-10-27
HRP20200814T1 (hr) 2020-08-07
CL2010001544A1 (es) 2012-02-03
LT2307454T (lt) 2017-05-25
KR102095257B1 (ko) 2020-04-01
NO2020021I1 (no) 2020-08-04
RU2531523C3 (ru) 2022-05-04
CA3020290A1 (en) 2009-12-30
CN110372792A (zh) 2019-10-25
US20180072802A1 (en) 2018-03-15
JP6821612B2 (ja) 2021-01-27
US9090684B2 (en) 2015-07-28
ES2622470T3 (es) 2017-07-06
PL3216803T3 (pl) 2020-10-19
JP7171877B6 (ja) 2024-02-06
NL301058I1 (es) 2020-07-31
CY1118829T1 (el) 2018-01-10
KR20110028518A (ko) 2011-03-18
RU2016119152A (ru) 2017-11-21
RU2747735C3 (ru) 2022-05-04
AU2009264565A1 (en) 2009-12-30
US10590193B2 (en) 2020-03-17
WO2009155724A3 (en) 2010-04-01
EP3216803B1 (en) 2020-03-11
CN102143976A (zh) 2011-08-03
BRPI0914251B1 (pt) 2022-07-19
RU2013133802A (ru) 2015-01-27
US20140004114A1 (en) 2014-01-02
RU2011102583A (ru) 2012-07-27
KR101817284B1 (ko) 2018-01-11
EP2307454A2 (en) 2011-04-13
DK2307454T3 (en) 2017-04-24
RU2019120079A (ru) 2020-12-28
EP3216803A1 (en) 2017-09-13
KR20180098705A (ko) 2018-09-04
RU2648152C2 (ru) 2018-03-22
KR101737466B1 (ko) 2017-05-18
RU2531523C9 (ru) 2015-04-10
JP2015134792A (ja) 2015-07-27
CN104961828A (zh) 2015-10-07
EP3722310A1 (en) 2020-10-14
LTPA2020004I1 (lt) 2020-08-10
JP2019162127A (ja) 2019-09-26
HUS2000028I1 (hu) 2020-08-28
HK1150844A1 (zh) 2012-01-13
US9873737B2 (en) 2018-01-23
JP2018108081A (ja) 2018-07-12
PT3216803T (pt) 2020-06-16
MX2011000011A (es) 2011-09-27
KR102157097B1 (ko) 2020-09-18
US8349322B2 (en) 2013-01-08
KR102296443B1 (ko) 2021-09-01
JP2022020782A (ja) 2022-02-01
HRP20170615T1 (hr) 2017-07-28
JP7171877B2 (ja) 2022-11-15
RU2588467C3 (ru) 2021-10-20
SI2307454T1 (sl) 2017-05-31
BRPI0914251A2 (pt) 2021-01-05
PT2307454T (pt) 2017-04-26
RU2531523C2 (ru) 2014-10-20
JP2014158491A (ja) 2014-09-04
JP2011525359A (ja) 2011-09-22
KR20170057462A (ko) 2017-05-24
KR20160128458A (ko) 2016-11-07
JP5956752B2 (ja) 2016-07-27
LT3216803T (lt) 2020-06-10
WO2009155724A2 (en) 2009-12-30
PL2307454T3 (pl) 2017-07-31
KR20180005753A (ko) 2018-01-16
HUE032894T2 (hu) 2017-11-28
CA2727839C (en) 2018-11-20
KR101671886B1 (ko) 2016-11-04
KR102013220B1 (ko) 2019-08-23
JP6100199B2 (ja) 2017-03-22
PH12015501593A1 (en) 2015-12-14
KR20150132602A (ko) 2015-11-25
JP6978468B2 (ja) 2021-12-08
RU2014132888A (ru) 2015-12-10
RU2747735C2 (ru) 2021-05-13
CN102143976B (zh) 2015-11-25
CA2727839A1 (en) 2009-12-30
EP2307454B1 (en) 2017-01-18

Similar Documents

Publication Publication Date Title
PH12015501593A1 (en) Stable and soluble antibodies inhibiting vegf
PH12019500438A1 (en) Anti-gcc antibody molecules and related compositions and methods
MX2011012039A (es) Anticuerpos bloqueadores anti-dkk-1 y sus usos.
UA115540C2 (uk) Антитіло до il-36r
UA115657C2 (uk) Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла
EP3593812A3 (en) Treatment of cancer using chimeric antigen receptor
MX2019006411A (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos.
TN2013000076A1 (en) Anti-ox40 antibodies and methods of using the same
MX357145B (es) Anticuerpos hacia gdf8 humano.
WO2011154139A3 (en) Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
UA116873C2 (uk) Антитіло, яке зв'язується з ox40
UA97516C2 (ru) Полностью человеческое моноклональное антитело против vap-1
MX353813B (es) Moleculas de union a vegf.
NZ591471A (en) Antibodies to ccr2
MX2010008096A (es) Anticuerpos de ferroportina y metodos de uso.
MX2012004084A (es) Anticuerpos siglec-15 para tratar enfermedad relacionada con perdida osea.
BR112012004823A8 (pt) Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica
MX2013008833A (es) Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
IN2014KN02933A (es)
UA105073C2 (uk) Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень
GB201003701D0 (en) System for the expression of a protein
MX2018015914A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina.
MX2015002465A (es) Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1).
MX2015014198A (es) Anticuerpos cuyo objetivo es m-csf.
WO2010094981A3 (en) Antibody therapy